ASSAL TAVAKOLI PARSA: Open Payments
NPI 1609348671 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 32 payments from 9 companies in 2025. Trend: 2023 $134 · 2024 $211 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $241 |
| Otsuka America Pharmaceutical, Inc. | 9 | $230 |
| ABBVIE INC. | 7 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Neos Therapeutics, LP | 3 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
Products named: FANAPT, REXULTI, VRAYLAR, TRINTELLIX, SPRAVATO, Adzenys XR-ODT, COBENFY, CAPLYTA.
Industry payments across CA — which companies pay providers there.
